Ministro da Saúde participa do Fifarma Annual Summit 2026, encontro que discute os novos desafios e oportunidades para a saúde no cenário latinoamericano

México enfrenta retrasos de casi seis años para aprobar fármacos, advierte la AMIIF. AMIIF alerta sobre rezago farmacéutico. Por Gabriela Díaz | Reportera En la inauguración de la 10ª Semana de la Innovación de la Asociación Mexicana de Industrias de Investigación Farmacéutica (AMIIF), Karla Alcázar, vicepresidenta primera del organismo, expuso que el sector salud tiene el deber de garantizar el acceso oportuno a medicamentos innovadores.

The FIFARMA Annual Summit 2026 highlights urgent strategies to enhance access to health innovations in Latin America, aiming for significant improvements in treatment accessibility and regional competitiveness.

On World Intellectual Property Day, FIFARMA emphasizes the importance of establishing favorable conditions for health innovations to thrive in Latin America.

Raquel Sorza, diretora de política em saúde da Fifarma, destaca fragilidades na propriedade intelectual e diz que país pode ganhar competitividade com ajustes regulatório

Patients in Latin America wait an average of 5.7 years to access innovative treatments after global approval. Although 9 out of 10 regulatory agencies in the region already use mechanisms such as Reliance, only one measures their real impact on reducing access times. The region reaches...

BOGOTA, Colombia, April 26, 2026 /PRNewswire/ -- On the occasion of World Intellectual Property Day (April 26), FIFARMA, the Latin American Federation of the Pharmaceutical Industry, highlights a key message: innovation in health is only possible when the right conditions are in place....